Pictured: Jedd Wolchok
MSK at ASCO
By Media Staff  |  Wednesday, June 4, 2014

Our experts offer their perspective in major media outlets on recent research into drug- and cell-based immunotherapies for cancer.

Pictured: Renier Brentjens, Isabelle Rivière & Michel Sadelain
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, February 20, 2014

A new study evaluating a cell-based immune therapy to treat an aggressive type of leukemia — the largest study of its kind to date — reports that 88 percent of patients responded to the treatment.

Pictured: Stem cell-derived nerve cells exposed to progerin
In the Lab
By Jennifer Bell, PhD  |  Monday, December 30, 2013

A team of Memorial Sloan Kettering scientists has come up with an approach to make stem-cell-derived neurons rapidly age in a cell culture dish. The breakthrough could transform research into Parkinson’s and other late-onset diseases.

Pictured: Michel Sadelain
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, December 18, 2012

Memorial Sloan Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.

Pictured: Isabelle Rivière and Michel Sadelain
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Monday, July 16, 2012

Memorial Sloan Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
Feature
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, December 28, 2011

Years of innovative research, technology development, and facility expansion at Memorial Sloan Kettering have led to several new experimental treatments for people with cancer.

Center News

Stay Informed

Get the latest information about cancer care and research every month.